- This event has passed.
UK-CAB 80: Long-acting agents, CROI and BHIVA feedback
23/04/2022 @ 9:30 AM - 4:00 PM
Date: 23 April 2022
Venue: Gorge House Trust, 75-77 Ardwick Green N, Manchester M12 6FX
Register for this meeting
Agenda
| Chair: Jo Josh | |
| 09.30-10.00 | Arrival, tea and refreshments, expenses |
| 09:50- 10.00 | Welcome and introductions UK-CAB updates |
| 10:00-11:00 | Long-acting agents (injectables) – setting the scene for longer-acting drugs and how they work? – Joshua Wharton – George House Trust; Alex Sparrowhawk – UK-CAB Chair |
| 11.00-11.15 | BREAK |
| 11.15-12.15 | CROI feedback – Simon Collins |
| 12.15-12.45 | Migrants and HIV; Ukraine and current policy – George Westwood, NAT |
| 12.45-13.45 | Lunch (will be delivered at venue) |
| Chair: Alex Sparrowhawk | |
| 13.45-14.45 | BHIVA Conference feedback by members Roger Pebody Ana Olivieria Rebecca Walker Jo Josh |
| 14.45-15:30 | UK-CAB online training programme – Ben Cromarty |
| 15:30 -16.00 | Members Updates Meeting reflection Any other business |
| 16.00 | Meeting close |
Background reading
HIV i-Base reports from CROI 2022:
ANTIRETROVIRALS
• Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
• Injectable CAB/RPV-LA: phase 3b ATLAS-2M results at three years
• Lenacapavir: 6-monthly dosing in treatment-experienced participants and as PrEP in macaques
• Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
• Islatravir studies for HIV treatment and PrEP
CURE-RELATED
• Fourth potential stem cell HIV cure – in a US woman using donor cord cells
• Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
• Targeting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
• Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
• No impact of high-dose vitamin D3 on reducing the HIV viral reservoir
COMPLICATIONS, INCLUDING COVID-19
• Risk factors for NAFLD and proteinuria in HIV positive people on ART
• ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
• Telomere shortening associated with TAF but not TDF in CHARTER study
HIV PREVENTION
• CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
• Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study